April 8, 2021
Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens 2 inflammation in airway cells.
Currently available SARS-CoV-2 therapeutics are targeted towards moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. While vaccines have demonstrated protective efficacy, vaccine hesitancy and logistical distribution... Read More